Case report: Zanubrutinib-induced dermatological toxicities: A single-center experience and review

Case report: Zanubrutinib-induced dermatological toxicities: A single-center experience and review

Zanubrutinib, a next-generation non-covalent Bruton’s tyrosine kinase (BTK) inhibitor, shows great efficacy in the treatment of B cell malignancies. Some patients may experience a series of side effects after the treatment of zanubrutinib. Grade 4 dermatological toxicities are rare, which present as...

Full description

Bibliographic Details
Main Authors: Lingling Wang, Jiao Tang, Jun Feng, Yongfen Huang, Yuexin Cheng, Hao Xu, Yuqing Miao
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-07-01
Series:Frontiers in Oncology
Subjects:
zanubrutinib
dermatological toxicity
maculopapule rash
papulopustular rash
skin infection
epithelial growth factor receptor
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.941633/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.941633/full

Similar Items